Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $114.98 million. The enterprise value is $66.80 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 62.83 million shares outstanding. The number of shares has increased by 6.33% in one year.
| Current Share Class | 62.83M |
| Shares Outstanding | 62.83M |
| Shares Change (YoY) | +6.33% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 5.96% |
| Owned by Institutions (%) | 22.65% |
| Float | 40.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.30 |
| Forward PS | n/a |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.35.
| Current Ratio | 3.41 |
| Quick Ratio | 3.20 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -91.43% and return on invested capital (ROIC) is -48.02%.
| Return on Equity (ROE) | -91.43% |
| Return on Assets (ROA) | -41.14% |
| Return on Invested Capital (ROIC) | -48.02% |
| Return on Capital Employed (ROCE) | -116.28% |
| Weighted Average Cost of Capital (WACC) | 10.43% |
| Revenue Per Employee | $247,464 |
| Profits Per Employee | -$1.42M |
| Employee Count | 56 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pyxis Oncology has paid $1.39 million in taxes.
| Income Tax | 1.39M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +45.24% in the last 52 weeks. The beta is 1.43, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | +45.24% |
| 50-Day Moving Average | 1.57 |
| 200-Day Moving Average | 2.18 |
| Relative Strength Index (RSI) | 59.45 |
| Average Volume (20 Days) | 418,986 |
Short Selling Information
The latest short interest is 2.27 million, so 3.61% of the outstanding shares have been sold short.
| Short Interest | 2.27M |
| Short Previous Month | 2.66M |
| Short % of Shares Out | 3.61% |
| Short % of Float | 5.62% |
| Short Ratio (days to cover) | 5.92 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $13.86 million and -$79.62 million in losses. Loss per share was -$1.28.
| Revenue | 13.86M |
| Gross Profit | 11.47M |
| Operating Income | -81.85M |
| Pretax Income | -78.24M |
| Net Income | -79.62M |
| EBITDA | -77.33M |
| EBIT | -81.85M |
| Loss Per Share | -$1.28 |
Full Income StatementBalance Sheet
The company has $66.86 million in cash and $18.67 million in debt, with a net cash position of $48.18 million or $0.77 per share.
| Cash & Cash Equivalents | 66.86M |
| Total Debt | 18.67M |
| Net Cash | 48.18M |
| Net Cash Per Share | $0.77 |
| Equity (Book Value) | 53.41M |
| Book Value Per Share | 0.85 |
| Working Capital | 50.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$63.50 million and capital expenditures -$9,000, giving a free cash flow of -$63.51 million.
| Operating Cash Flow | -63.50M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 4.51M |
| Net Borrowing | n/a |
| Free Cash Flow | -63.51M |
| FCF Per Share | -$1.01 |
Full Cash Flow StatementMargins
| Gross Margin | 82.77% |
| Operating Margin | -590.60% |
| Pretax Margin | -564.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.33% |
| Shareholder Yield | -6.33% |
| Earnings Yield | -69.25% |
| FCF Yield | -55.24% |
Analyst Forecast
The average price target for Pyxis Oncology is $6.83, which is 273.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.83 |
| Price Target Difference | 273.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 61.06% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -7.09 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.09 |
| Piotroski F-Score | 2 |
